10-Q Filing

BIO-PATH HOLDINGS, INC. CIK: 1133818 Q1 2019

Filing Information

Form Type	10-Q
Accession Number	`0001144204-19-026590`
Period End Date	20190331
Filing Date	20190515
Fiscal Year	2019
Fiscal Period	Q1
XBRL Instance	bpth-20190331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 62 Income Statement 18 Cash Flow Statement 43 Stockholders Equity 16

Balance Sheet 62 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Cash	`Cash`	$19.28M	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	2.81M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	680,000.00	shares	Point-in-time
Cash	`Cash`	$1.00M	USD	Point-in-time
Cash	`Cash`	$4.28M	USD	Point-in-time
Cash	`Cash`	$5.96M	USD	Point-in-time
Prepaid drug product for testing	`PrepaidExpenseCurrent`	$332.00K	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	2.81M	shares	Point-in-time
Prepaid drug product for testing	`PrepaidExpenseCurrent`	$427.00K	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	680,000.00	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$593.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.16M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.93M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$20.87M	USD	Point-in-time
Furniture, fixtures & equipment	`PropertyPlantAndEquipmentGross`	$998.00K	USD	Point-in-time
Furniture, fixtures & equipment	`PropertyPlantAndEquipmentGross`	$998.00K	USD	Point-in-time
Less accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$658.00K	USD	Point-in-time
Less accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$592.00K	USD	Point-in-time
Property, Plant and Equipment, Net	`PropertyPlantAndEquipmentNet`	$340.00K	USD	Point-in-time
Property, Plant and Equipment, Net	`PropertyPlantAndEquipmentNet`	$406.00K	USD	Point-in-time
Right of use operating assets	`OperatingLeaseRightOfUseAsset`	-	USD	Point-in-time
Right of use operating assets	`OperatingLeaseRightOfUseAsset`	$113.00K	USD	Point-in-time
Total Assets	`Assets`	$2.33M	USD	Point-in-time
Total Assets	`Assets`	$21.32M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$813.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$607.00K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$456.00K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$304.00K	USD	Point-in-time
Current portion of lease liabilities	`OperatingLeaseLiabilityCurrent`	-	USD	Point-in-time
Current portion of lease liabilities	`OperatingLeaseLiabilityCurrent`	$54.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.12M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.12M	USD	Point-in-time
Noncurrent lease liabilities	`OperatingLeaseLiabilityNoncurrent`	-	USD	Point-in-time
Noncurrent lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$59.00K	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.12M	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.18M	USD	Point-in-time
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $.001 par value; 200,000 shares authorized; 2,814 and 680 shares issued and outstanding, respectively	`CommonStockValue`	$1.00K	USD	Point-in-time
Common stock, $.001 par value; 200,000 shares authorized; 2,814 and 680 shares issued and outstanding, respectively	`CommonStockValue`	$3.00K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$69.39M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$48.96M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-49.25M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-47.74M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$6.28M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$1.22M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$8.07M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$20.14M	USD	Point-in-time
Total Liabilities & Shareholders' Equity	`LiabilitiesAndStockholdersEquity`	$2.33M	USD	Point-in-time
Total Liabilities & Shareholders' Equity	`LiabilitiesAndStockholdersEquity`	$21.32M	USD	Point-in-time

Income Statement 18 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$398.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$932.00K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$987.00K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$1.12M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$1.92M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$1.52M	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-1.52M	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-1.92M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$8.00K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$3.00K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$3.00K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$8.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.92M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.51M	USD	1 Quarter
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.89	USD	1 Quarter
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-3.38	USD	1 Quarter
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	1.70M	shares	1 Quarter
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	567,000.00	shares	1 Quarter

Cash Flow Statement 43 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-1.92M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.51M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$157.00K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$124.00K	USD	1 Quarter
Amortization of technology license	`AmortizationOfIntangibleAssets`	-	USD	1 Quarter
Amortization of technology license	`AmortizationOfIntangibleAssets`	$40.00K	USD	1 Quarter
Amortization of right of use assets	`OperatingLeaseRightOfUseAssetsAmortization`	-	USD	1 Quarter
Amortization of right of use assets	`OperatingLeaseRightOfUseAssetsAmortization`	$28.00K	USD	1 Quarter
Depreciation	`Depreciation`	$66.00K	USD	1 Quarter
Depreciation	`Depreciation`	$66.00K	USD	1 Quarter
Prepaid drug product for testing	`IncreaseDecreaseInPrepaidExpense`	$95.00K	USD	1 Quarter
Prepaid drug product for testing	`IncreaseDecreaseInPrepaidExpense`	$139.00K	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$570.00K	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-23.00K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$138.00K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-54.00K	USD	1 Quarter
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilties`	$28.00K	USD	1 Quarter
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilties`	-	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.01M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.66M	USD	1 Quarter
Purchases of furniture, fixtures & equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	-	USD	1 Quarter
Purchases of furniture, fixtures & equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$17.00K	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	1 Quarter
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-17.00K	USD	1 Quarter
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$1.50M	USD	Point-in-time
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$17.00M	USD	Point-in-time
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$19.41M	USD	1 Quarter
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	1 Quarter
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$900.00K	USD	Point-in-time
Net proceeds from exercise of warrants	`ProceedsFromStockOptionsExercised`	-	USD	1 Quarter
Net proceeds from exercise of warrants	`ProceedsFromStockOptionsExercised`	$869.00K	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	-	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$20.28M	USD	1 Quarter
Net increase (decrease) in cash	`CashPeriodIncreaseDecrease`	$18.27M	USD	1 Quarter
Net increase (decrease) in cash	`CashPeriodIncreaseDecrease`	$-1.68M	USD	1 Quarter
Cash, beginning of period	`Cash`	$19.28M	USD	Point-in-time
Cash, beginning of period	`Cash`	$1.00M	USD	Point-in-time
Cash, beginning of period	`Cash`	$4.28M	USD	Point-in-time
Cash, beginning of period	`Cash`	$5.96M	USD	Point-in-time
Cash, end of period	`Cash`	$19.28M	USD	Point-in-time
Cash, end of period	`Cash`	$1.00M	USD	Point-in-time
Cash, end of period	`Cash`	$4.28M	USD	Point-in-time
Cash, end of period	`Cash`	$5.96M	USD	Point-in-time

Stockholders Equity 16 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance	`StockholdersEquity`	$6.28M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$1.22M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$8.07M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$20.14M	USD	Point-in-time
Issuance of common stock, net of fees	`StockIssuedDuringPeriodValueNewIssues`	$19.41M	USD	1 Quarter
Issuance of common stock, net of fees	`StockIssuedDuringPeriodValueNewIssues`	$1.70M	USD	Point-in-time
Issuance of common stock, net of fees (in shares)	`StockIssuedDuringPeriodSharesNewIssues`	648,233.00	shares	Point-in-time
Exercise of warrants, net of fees	`StockIssueDuringPeriodValueWarrantsExercised`	$869.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalOther`	$124.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalOther`	$157.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.92M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.51M	USD	1 Quarter
Ending Balance	`StockholdersEquity`	$6.28M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$1.22M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$8.07M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$20.14M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.